Swiss National Bank
VERV

Swiss National Bank’s Verve Therapeutics VERV Stock Holding History

Swiss National Bank’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-110,200
Closed -$1.24M – 2367
2025
Q2 		$1.24M Sell
110,200
-12,900
-10% -$73.5K ﹤0.01% 2041
2025
Q1 		$563K Sell
123,100
-10,000
-8% -$67K ﹤0.01% 2321
2024
Q4 		$751K Buy
133,100
+18,000
+16% +$102K ﹤0.01% 2319
2024
Q3 		$557K Hold
115,100
– – ﹤0.01% 2414
2024
Q2 		$562K Buy
115,100
+11,900
+12% +$74.8K ﹤0.01% 2393
2024
Q1 		$1.37M Sell
103,200
-5,300
-5% -$70.3K ﹤0.01% 2058
2023
Q4 		$1.51M Buy
108,500
+13,200
+14% +$164K ﹤0.01% 2003
2023
Q3 		$1.26M Buy
95,300
+7,700
+9% +$124K ﹤0.01% 2107
2023
Q2 		$1.64M Buy
87,600
+14,500
+20% +$241K ﹤0.01% 2020
2023
Q1 		$1.05M Sell
73,100
-6,500
-8% -$127K ﹤0.01% 2222
2022
Q4 		$1.54M Buy
79,600
+3,300
+4% +$87.4K ﹤0.01% 2063
2022
Q3 		$2.62M Buy
76,300
+30,900
+68% +$986K ﹤0.01% 1693
2022
Q2 		$694K Buy
45,400
+5,500
+14% +$85.2K ﹤0.01% 2524
2022
Q1 		$911K Buy
39,900
+3,000
+8% +$85.7K ﹤0.01% 2452
2021
Q4 		$1.36M Buy
+36,900
New +$1.55M ﹤0.01% 2292

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Swiss National Bank's VERV Position: Q3 2025 in Review

Swiss National Bank sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 110,200 shares — an estimated $1.24M sold.

Swiss National Bank first reported a position in VERV in Q4 2021 and held it in 15 quarters. The position peaked at $2.62M in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Swiss National Bank reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Swiss National Bank sold 110,200 Verve Therapeutics shares in Q3 2025, an estimated $1.24M.
  • Swiss National Bank first reported a position in Verve Therapeutics in Q4 2021 and held it in 15 quarters.
  • Swiss National Bank's Verve Therapeutics position peaked at $2.62M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Swiss National Bank's 13F filing for Q3 2025, filed 13 Nov 2025.